Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01640275 · ClinicalTrials.gov registry record · Phase 1
Markers of Alzheimers Disease After Propofol or Isoflurane Anesthesia
A Phase 1 study, sponsored by Duke University.
- Completed
- Registry status
- Phase 1
- Development phase
- 105
- Enrollment target
NCT01640275 is a Phase 1 study that has completed, run by Duke University. The registered enrollment target is 105 participants.
The verdict
NCT01640275, a Phase 1 study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 105 participants
- Enrollment target
Study Summary
Previous work in animal models suggests that inhalational anesthetic agents may accelerate Alzheimer's disease pathogenesis, but it is unclear to what extent this may happen in humans. Here, the investigators propose to measure Alzheimer's disease-related neural markers in the cerebrospinal fluid (CSF) of patients exposed to anesthesia while undergoing neurosurgical procedures that require lumbar drain placement. Patients will be randomized to either receive inhalation anesthesia with isoflurane or intravenous anesthesia with propofol. CSF and blood samples will each be collected at the induction of anesthesia, and then again ten and twenty-four hours later. CSF samples will be assayed for amyloid beta, tau, and other Alzheimer's disease-associated markers; blood samples will be assayed for serum inflammatory markers and used for genotyping studies. These studies should clarify the effect of common anesthetic agents on Alzheimer's disease related neural markers.
Interventions
- DRUG Propofol
- DRUG Isoflurane
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2012-03 |
| Est. Completion | 2015-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01640275
The ClinicalTrials.gov registry entry for NCT01640275 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 105 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Propofol is the first listed.
NCT01640275 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01640275 about?
NCT01640275 is a clinical study titled "Markers of Alzheimers Disease After Propofol or Isoflurane Anesthesia". Previous work in animal models suggests that inhalational anesthetic agents may accelerate Alzheimer's disease pathogenesis, but it is unclear to what extent this may happen in humans. Here, the investigators propose to measure Alzheimer's disease-related neural markers in the cerebrospinal fluid (C...
What is the current status of trial NCT01640275?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 105 participants. The study started on 2012-03. Estimated completion is 2015-03.
What interventions are being tested in trial NCT01640275?
The interventions under investigation include: Propofol (DRUG), Isoflurane (DRUG).
Who is sponsoring clinical trial NCT01640275?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.